At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. To achieve this, we pursue an integrated access strategy that focuses our work on improving access to medicines, access to medical information and access to medical capacity building, which includes efforts to provide and support appropriate training for healthcare professionals. In 2015, our products reached an estimated 520 million patients and our aspiration is to reach 1 billion people.
In addition to the global No. 1 ranking in biosimilars and generic antibiotics, dermatology and transplantation medicines, Sandoz, a Novartis company, holds leading global positions in areas ranging from generic cardiovascular, central nervous system (CNS), pain and ophthalmology to oncology, respiratory and hormonal therapeutics.
Whether the cause be an aging population, changing lifestyle patterns or poor economic outlook, healthcare systems around the world are struggling to cope with the reality of increasing cost containment pressures. But this challenge is not without a solution: generic pharmaceuticals provide significant savings for patients and healthcare systems alike. Generics free up resources for the funding of costlier novel therapies, benefiting patients and incentivizing investment in new, innovative medicines that target unmet medical needs. Sandoz plays an important role in the healthcare system.
We are eager to do everything in our power to meet patients’ medical needs while achieving the highest standards of quality, compliance and service, as well as supplying products at the best possible cost.
Our broad portfolio is backed by a range of state-of-the-art technologies, formulations and devices, including a large portfolio of high-quality generic medicines composed of solid orals, patches, ointment/creams, antibiotics and lyophilised products, biosimilars and specialty and over-the-counter (OTC) products.
A trusted partner of pharmacists and the healthcare sector, we have the most reliable supply chain in the industry, according to the Pharmacy Advantage Report, as well as a well-established salesforce and a large distribution network.
In addition to a Development Center with deep scientific expertise and a Commercial Operations group, our Boucherville campus comprises the largest generic sterile injectable production plant in Canada. It manufactures vitally important injectable medicines in different formats that are used in hospitals and long-term care centers across the country. The Boucherville facility is part of the Novartis Technical Operations organization, whose mission is to help millions of patients by making medicines, on time, every time, safely and efficiently.
A proven track record across the globe:
We have strong scientific roots that have driven many medical innovations, from the first oral penicillin in 1951 to the first biosimilars in Europe and the US; new delivery technologies (e.g. our award-winning Forspiro inhaler or our Fentanyl patch technology) offer genuine improvements over alternative market offerings. We go beyond providing standard products and add value to the healthcare system through a range of support services and value-added medicines including combination formulations. Examples include the “Sandoz Pro” healthcare professionals app pioneered by Sandoz Canada and the “three-in-one” cardiovascular “polypill” launched by Sandoz Germany in 2015.
Increasing access to medicine is the basis of our day-to-day business model, but we also run a range of targeted corporate responsibility programs to ensure access for those most in need. These programs aim to address specific health needs in underprivileged communities, promote access to medical information and help build capacity.